| Objective:Observing the effects of Baoyuan Zhuyu Decoction on heart function grading,ultrasound index(LVED,LVEF,LAD),inflammatory factors(hs CRP,NT proBNP,CysC HCY,Lp PLA2),quality of life score,6-minute walking ability,traditional Chinese medicine syndrome score,adverse reactions and other aspects in patients with heart failure(Qi deficiency and blood stasis type),objective analysis and evaluation of its clinical efficacy and safety.Methods:Select 60 patients from the Cardiovascular Department of the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine from May 2020 to December 2021,who meet the criteria and belong to the Qi Deficiency and Blood Stasis syndrome of heart failure cases.Number them according to the order of admission and treatment time.Then use a random number table to randomly select and divide them into a treatment group and a control group,with 30 patients in both groups.Both groups of patients received basic treatment for primary diseases such as blood pressure control and lowering blood sugar and blood lipids,while providing guidance on reasonable diet(such as eating a low salt and low sugar diet,exercising appropriately,quitting smoking and alcohol,and taking oxygen,etc.).The control group received routine Western medicine treatment(using four drugs:furosemide tablets,spironolactone tablets,betaloc,and captopril,with dosage guidance for patients),while the treatment group received basic Western medicine treatment while also taking traditional Chinese medicine formula(Baoyuan Zhuyu Decoction)for treatment(with adjustments made according to the patient’s condition during the treatment period),with a course of one month.Compare the changes in cardiac function grading,ultrasound index(LVED,LVEF,LAD),inflammatory factors(hs CRP,NT proBNP,CysC HCY,Lp PLA2),quality of life score,6-minute walking ability,and traditional Chinese medicine syndrome score between two groups of patients during treatment,and record the adverse events during the patient’s medication process.After statistical analysis using SPSS26.0 software,Evaluate the clinical efficacy and safety of Baoyuan Zhuyu Decoction in treating patients with heart failure(Qi deficiency and blood stasis type).Result:1.Comparison of general data between the two groups of patients:There was no significant difference in baseline data(age,course of disease,cardiac function grading,traditional Chinese medicine syndrome score)between the two groups of patients(p>0.05),and the difference was not statistically significant.2.Comparison of NYHA cardiac function efficacy between two groups of patients:Both groups of patients’ conditions have been alleviated and improved to varying degrees.Based on the NYHA cardiac function grading efficacy evaluation criteria,the total effective rate of the treatment group is as high as 90%,significantly higher than the control group’s 70.00%(x2=4.812,p<0.05),with statistically significant differences.3.Comparison of total TCM symptom scores between two groups of patients:After treatment,the TCM syndrome scores of the treatment group(26.31 ± 2.42)were significantly higher than those before treatment(56.48 ±2.48)(t=47.689,p<0.01)and the control group(t=34.642,34.88 ± 2.38)(p<0.05),with statistical significance.4.Comparison of traditional Chinese medicine syndrome efficacy between two groups of patients:The total effective rate of traditional Chinese medicine syndrome efficacy between the two groups was compared,and the total effective rate of the treatment group was as high as 86.7%,significantly higher than the control group’s 66.7%(x2=The difference was statistically significant(3.354,p<0.05).5.Comparison of inflammatory factor levels between two groups of patients:After treatment,the severity factor levels of both groups of patients improved to a certain extent,significantly better than before treatment(p<0.01),while the treatment group’s various indicators showed that CRP(0.73 ± 0.38),BNP(628.13 ± 5.19),CysC(0.62 ± 0.11),HCY(7.18 ± 0.88),Lp PLA2(23.11 ± 2.12)were significantly better than the control group’s CRP(0.98 ± 0.46),BNP(1055.21 ± 4.38),CysC(0.72 ± 0.10),HCY(10.12 ±0.12),Lp PLA2(57.18 ± 3.28).(p<0.05),The difference is statistically significant.6.Comparison of cardiac ultrasound indices between two groups of patients:There was no significant difference in LVED,LVEF,and LAD indices between the two groups before treatment(p>0.05).After treatment,LVED(138.01 ± 7.42),LVEF(50.32 ± 4.18),and LAD(35.25 ± 4.26)in the treatment group were significantly higher than those before treatment(56.88± 6.47),LVEF(40.38 ± 7.24),and LAD(20.42 ± 5.88),with a significant difference(p<0.01),and significantly higher than those in the control group(109.25 ± 8.12),LVEF(46.22 ± 5.42),and LAD(26.62 ± 4.42)(p<0.05).7.Comparison of six minute walking test mobility between two groups of patients:Both groups of patients showed some improvement in walking mobility,with the treatment group having a significantly higher score in the six minute walking test(467.18 ± 52.13)compared to before treatment(242.48 ± 56.72)(t=16.323,p<0.01).The treatment group had a significantly higher score than the control group(402.62 ± 50.18)(t=12.742,p<0.05),and the difference was statistically significant.8.Comparison of quality of life scores between two groups of patients:After treatment,the quality of life of both groups of patients has been improved to a certain extent.The quality of life score of the treatment group(15.44 ± 1.21)is significantly higher than before treatment(t=3 1.971,p<0.01)and the control group(t=14.564,p<0.01),and the difference is statistically significant.9.Comparison of adverse reactions between the two groups of patients during treatment:during treatment,both groups of patients had certain adverse reactions,such as dyspnea,fluid retention,fatigue and fatigue.The rate of adverse reactions in the treatment group was as low as 6.67%,significantly lower than that in the control group(23.33%),with statistical significance.10.There was no significant difference between the two groups of patients in terms of normal,mild,moderate,and severe Western medical signs before treatment,and there was no statistical significance(p>0.05);After treatment,the Western medicine physical signs in the treatment group increased significantly and were higher than those before treatment and the control group(p<0.05),while the severity decreased significantly and was lower than those before treatment and the control group(p<0.05).The difference was statistically significant.Conclusion:1.Baoyuan Zhuyu decoction can improve the cardiac structure and ultrasound index of CHF patients with qi deficiency and blood stasis;2.Baoyuan Zhuyu decoction can reduce the total score of medical syndrome in patients with qi deficiency and blood stasis CHF;3.Baoyuan Zhuyu decoction can reduce the index of qi deficiency and blood stasis CHF inflammation influencing factor index;4.Baoyuan Zhuyu decoction can improve qi deficiency and blood stasis type CHF heart function,NYHA improve quality of life,and increase 6-minute walking tolerance;5.Baoyuan Zhuyu decoction can effectively protect the physical functions of patients,with fewer clinical adverse reactions and high clinical safety. |
PDF Full Text Request